Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 1
2016 2
2018 1
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Eggermont AM, et al. Among authors: de schaetzen g. Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Lancet Oncol. 2015. PMID: 25840693 Clinical Trial.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Eggermont AM, et al. Among authors: de schaetzen g. N Engl J Med. 2016 Nov 10;375(19):1845-1855. doi: 10.1056/NEJMoa1611299. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717298 Free PMC article. Clinical Trial.
Socio-economic outcomes among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: Results of the 58LAE study.
Barbati M, Kicinski M, Suciu S, Mazingue F, Vandecruys E, Plat G, Uyttebroeck A, Paillard C, Dresse MF, Simon P, Pluchart C, Minckes O, Ferster A, Freycon C, Millot F, Van Der Werff Ten Bosch J, Chantrain C, Paulus R, de Schaetzen G, Rossi G, Rohrlich P, Benoit Y, Piette C; European Organisation for Research and Treatment of Cancer (EORTC) Children's Leukemia Group (CLG). Barbati M, et al. Among authors: de schaetzen g. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13755. doi: 10.1111/ecc.13755. Epub 2022 Oct 25. Eur J Cancer Care (Engl). 2022. PMID: 36284405 Free PMC article.
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.
Ramadan SM, Suciu S, Stevens-Kroef MJPL, Willemze R, Amadori S, de Witte T, Löwenberg B, Muus P, Labar B, Meert L, de Schaetzen G, Meloni G, Leone G, Vignetti M, Marie JP, Lübbert M, Baron F. Ramadan SM, et al. Among authors: de schaetzen g. Cancers (Basel). 2020 Nov 11;12(11):3334. doi: 10.3390/cancers12113334. Cancers (Basel). 2020. PMID: 33187229 Free PMC article.
Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58 Late Adverse Effects study.
Rossi G, Kicinski M, Suciu S, Vandecruys E, Plat G, Uyttebroeck A, Paillard C, Barbati M, Dresse MF, Simon P, Minckes O, Pluchart C, Ferster A, Freycon C, Millot F, van der Werff Ten Bosch J, Chantrain C, Paulus R, de Rojas T, de Schaetzen G, Rohrlich P, Benoit Y, Piette C. Rossi G, et al. Among authors: de schaetzen g. Hum Reprod. 2021 Dec 27;37(1):44-53. doi: 10.1093/humrep/deab236. Hum Reprod. 2021. PMID: 34788455 Free article.
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Eggermont AM, et al. Among authors: de schaetzen g. J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24. J Clin Oncol. 2012. PMID: 23008300 Clinical Trial.
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group. Eggermont AM, et al. Among authors: de schaetzen g. Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17. Eur J Cancer. 2016. PMID: 26790144 Clinical Trial.